{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T23:42:57Z","timestamp":1788824577843,"version":"build-2803163510"},"reference-count":67,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Affective Disorders"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.jad.2024.04.039","type":"journal-article","created":{"date-parts":[[2024,4,16]],"date-time":"2024-04-16T05:57:27Z","timestamp":1713247047000},"page":"753-762","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"special_numbering":"C","title":["Number needed to treat (NNT) for ketamine and esketamine in adults with treatment-resistant depression: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"356","author":[{"given":"Cameron N.","family":"Calder","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela T.H.","family":"Kwan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kayla M.","family":"Teopiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua D.","family":"Rosenblat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodrigo B.","family":"Mansur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taeho Greg","family":"Rhee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger S.","family":"McIntyre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jad.2024.04.039_bb0005","doi-asserted-by":"crossref","first-page":"663","DOI":"10.7326\/0003-4819-134-8-200104170-00012","article-title":"The revised CONSORT statement for reporting randomized trials: explanation and elaboration","volume":"134","author":"Altman","year":"2001","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.jad.2024.04.039_bb0010","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1056\/NEJMoa2302399","article-title":"Ketamine versus ECT for non-psychotic treatment-resistant major depression","volume":"388","author":"Anand","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jad.2024.04.039_bb0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.psychres.2021.114058","article-title":"Neurocognitive aspects of ketamine and esketamine on subjects with treatment-resistant depression: a comparative, randomized and double-blind study","volume":"303","author":"Ara\u00fajo-de-Freitas","year":"2021","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.jad.2024.04.039_bb0020","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1071\/HC16008","article-title":"Antidepressants for treatment of depression in primary care: a systematic review and meta-analysis","volume":"8","author":"Arroll","year":"2016","journal-title":"J. Prim. Health Care"},{"key":"10.1016\/j.jad.2024.04.039_bb0025","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1136\/ebmental-2019-300117","article-title":"How to perform a meta-analysis with R: a practical tutorial","volume":"22","author":"Balduzzi","year":"2019","journal-title":"Evid. Based Ment. Health"},{"key":"10.1016\/j.jad.2024.04.039_bb0030","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1002\/da.22060","article-title":"Efficacy and acceptability of high frequency repetitive Transcranial Magnetic Stimulation (rTMS) versus Electroconvulsive Therapy (ECT) for major depression: a systematic review and meta-analysis of randomized trials","volume":"30","author":"Berlim","year":"2013","journal-title":"Depress. Anxiety"},{"key":"10.1016\/j.jad.2024.04.039_bb0035","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1002\/da.22505","article-title":"Ketamine for treatment-resistant unipolar and bipolar major depression: critical review and implications for clinical practice","volume":"33","author":"Bobo","year":"2016","journal-title":"Depress. Anxiety"},{"key":"10.1016\/j.jad.2024.04.039_bb0040","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/S0140-6736(19)30934-1","article-title":"New WHO prevalence estimates of mental disorders in conflict settings: a systematic review and meta-analysis","volume":"394","author":"Charlson","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.jad.2024.04.039_bb0045","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.jad.2017.09.008","article-title":"Persistent antidepressant effect of low-dose ketamine and activation in the supplementary motor area and anterior cingulate cortex in treatment-resistant depression: a randomized control study","volume":"225","author":"Chen","year":"2018","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jad.2024.04.039_bb3000","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1192\/bjp.209.3.262b","article-title":"NNT and NNH remain helpful in evidence-based medicine","volume":"209","author":"Citrome","year":"2016","journal-title":"Br. J. Psych."},{"key":"10.1016\/j.jad.2024.04.039_bb0050","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.jad.2020.03.106","article-title":"Appraising esketamine nasal spray for the management of treatment-resistant depression in adults: number needed to treat, number needed to harm, and likelihood to be helped or harmed","volume":"271","author":"Citrome","year":"2020","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jad.2024.04.039_bb0060","doi-asserted-by":"crossref","first-page":"3051","DOI":"10.2147\/DDDT.S221437","article-title":"Ketamine and depression: a narrative review","volume":"13","author":"Corriger","year":"2019","journal-title":"Drug Des. Devel. Ther."},{"key":"10.1016\/j.jad.2024.04.039_bb0065","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1002\/hup.2475","article-title":"The use of ketamine as an antidepressant: a systematic review and meta-analysis","volume":"30","author":"Coyle","year":"2015","journal-title":"Hum. Psychopharmacol."},{"key":"10.1016\/j.jad.2024.04.039_bb0070","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1093\/oxfordjournals.aje.a009523","article-title":"Confidence limits made easy: interval estimation using a substitution method","volume":"147","author":"Daly","year":"1998","journal-title":"Am. J. Epidemiol."},{"key":"10.1016\/j.jad.2024.04.039_bb0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.psychres.2023.115133","article-title":"Real world effectiveness of repeated ketamine infusions for treatment-resistant depression with comorbid borderline personality disorder","volume":"323","author":"Danayan","year":"2023","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.jad.2024.04.039_bb0080","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.jad.2023.12.038","article-title":"The rapid antidepressant effectiveness of repeated dose of intravenous ketamine and intranasal esketamine: a post-hoc analysis of pooled real-world data","volume":"348","author":"d\u2019Andrea","year":"2024","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jad.2024.04.039_bb0085","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1002\/da.22975","article-title":"Ketamine for acute suicidal ideation. An emergency department intervention: a randomized, double-blind, placebo-controlled, proof-of-concept trial","volume":"37","author":"Domany","year":"2020","journal-title":"Depress. Anxiety"},{"key":"10.1016\/j.jad.2024.04.039_bb0090","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1038\/s41380-018-0311-2","article-title":"Correction: double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD)","volume":"25","author":"Fava","year":"2020","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.jad.2024.04.039_bb0095","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1093\/ijnp\/pyz039","article-title":"Efficacy and safety of fixed-dose esketamine nasal spray combined with a new oral antidepressant in treatment-resistant depression: results of a randomized, double-blind, active-controlled study (TRANSFORM-1)","volume":"22","author":"Fedgchin","year":"2019","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.jad.2024.04.039_bb0100","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1176\/appi.ajp.2021.21030277","article-title":"Adjunctive ketamine with relapse prevention\u2013based psychological therapy in the treatment of alcohol use disorder","volume":"179","author":"Grabski","year":"2022","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jad.2024.04.039_bb0105","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1176\/appi.ajp.2017.17060647","article-title":"Ketamine for rapid reduction of suicidal thoughts in major depression: a midazolam-controlled randomized clinical trial","volume":"175","author":"Grunebaum","year":"2018","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jad.2024.04.039_bb0110","doi-asserted-by":"crossref","first-page":"e42","DOI":"10.1016\/S0140-6736(18)32408-5","article-title":"Reducing the global burden of depression: a Lancet\u2013World Psychiatric Association Commission","volume":"393","author":"Herrman","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.jad.2024.04.039_bb0115","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.jad.2024.04.039_bb0120","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1017\/S0033291715002159","article-title":"Single i.v. ketamine augmentation of newly initiated escitalopram for major depression: results from a randomized, placebo-controlled 4-week study","volume":"46","author":"Hu","year":"2016","journal-title":"Psychol. Med."},{"key":"10.1016\/j.jad.2024.04.039_bb0125","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.jad.2018.09.037","article-title":"Repeat-dose ketamine augmentation for treatment-resistant depression with chronic suicidal ideation: a randomized, double blind, placebo controlled trial","volume":"243","author":"Ionescu","year":"2019","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jad.2024.04.039_bb0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2022.109299","article-title":"The therapeutic role of ketamine and esketamine in treating psychopathological domains of depression","volume":"223","author":"Jawad","year":"2023","journal-title":"Neuropharmacol"},{"key":"10.1016\/j.jad.2024.04.039_bb0135","doi-asserted-by":"crossref","first-page":"909","DOI":"10.3390\/brainsci13060909","article-title":"The role of ketamine in the treatment of bipolar depression: a scoping review","volume":"13","author":"Jawad","year":"2023","journal-title":"Brain Sci."},{"key":"10.1016\/j.jad.2024.04.039_bb0140","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1007\/s40263-014-0171-5","article-title":"Early switching strategies in anti-depressant non-responders: current evidence and future research directions","volume":"28","author":"Kudlow","year":"2014","journal-title":"CNS Drugs"},{"key":"10.1016\/j.jad.2024.04.039_bb0145","article-title":"Pre-treatment pain symptoms influence antidepressant response to ketamine in depressive patients","volume":"13","author":"Lan","year":"2022","journal-title":"Front. Psych."},{"key":"10.1016\/j.jad.2024.04.039_bb0150","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1016\/j.biopsych.2014.03.026","article-title":"A randomized controlled trial of intranasal ketamine in major depressive disorder","volume":"76","author":"Lapidus","year":"2014","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.jad.2024.04.039_bb0155","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.jad.2022.08.050","article-title":"The association between stage of treatment-resistant depression and clinical utility of ketamine\/esketamine: a systematic review","volume":"318","author":"Levinta","year":"2022","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jad.2024.04.039_bb0160","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1002\/hbm.23085","article-title":"The effects of low-dose ketamine on the prefrontal cortex and amygdala in treatment-resistant depression: a randomized controlled study","volume":"37","author":"Li","year":"2016","journal-title":"Hum. Brain Mapp."},{"key":"10.1016\/j.jad.2024.04.039_bb0165","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1192\/bjp.2023.79","article-title":"Efficacy and safety of a 4-week course of repeated subcutaneous ketamine injections for treatment-resistant depression (KADS study): randomised double-blind active-controlled trial","volume":"223","author":"Loo","year":"2023","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.jad.2024.04.039_bb0170","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.jad.2020.09.007","article-title":"A systematic review and meta-analysis of the efficacy of intravenous ketamine infusion for treatment resistant depression: January 2009 \u2013 January 2019","volume":"277","author":"Marcantoni","year":"2020","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jad.2024.04.039_bb0175","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.jad.2022.09.043","article-title":"Real-world experience of esketamine use to manage treatment-resistant depression: a multicentric study on safety and effectiveness (REAL-ESK study)","volume":"319","author":"Martinotti","year":"2022","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jad.2024.04.039_bb0180","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1001\/jamapsychiatry.2023.3979","article-title":"Choosing between ketamine and electro-convulsive therapy for outpatients with treatment-resistant depression\u2014advantage ketamine?","volume":"80","author":"Mathew","year":"2023","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.jad.2024.04.039_bb0185","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/j.jad.2020.06.050","article-title":"The effect of intravenous, intranasal, and oral ketamine in mood disorders: a meta-analysis","volume":"276","author":"McIntyre","year":"2020","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jad.2024.04.039_bb0190","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1177\/0269881120954048","article-title":"The effectiveness of intravenous ketamine in adults with treatment-resistant major depressive disorder and bipolar disorder presenting with prominent anxiety: results from the Canadian Rapid Treatment Center of Excellence","volume":"35","author":"McIntyre","year":"2020","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.jad.2024.04.039_bb0195","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1176\/appi.ajp.2020.20081251","article-title":"Synthesizing the evidence for ketamine and esketamine in treatment-resistant depression: an international expert opinion on the available evidence and implementation","volume":"178","author":"McIntyre","year":"2021","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jad.2024.04.039_bb0200","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1002\/wps.21120","article-title":"Treatment-resistant depression: definition, prevalence, detection, management, and investigational interventions","volume":"22","author":"McIntyre","year":"2023","journal-title":"World Psychiatry"},{"key":"10.1016\/j.jad.2024.04.039_bb0205","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1471-2288-2-2","article-title":"Pooling data for number needed to treat: no problems for apples","volume":"2","author":"Moore","year":"2002","journal-title":"BMC Med. Res. Methodol."},{"key":"10.1016\/j.jad.2024.04.039_bb0210","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1176\/appi.ajp.2013.13030392","article-title":"Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial","volume":"170","author":"Murrough","year":"2013","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jad.2024.04.039_bb0215","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1080\/14740338.2022.2066651","article-title":"Long-term safety of ketamine and esketamine in treatment of depression","volume":"21","author":"Nikayin","year":"2022","journal-title":"Expert Opin. Drug Saf."},{"key":"10.1016\/j.jad.2024.04.039_bb0220","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1001\/jamapsychiatry.2022.1074","article-title":"Evaluation of the trajectory of depression severity with ketamine and esketamine treatment in a clinical setting","volume":"79","author":"Nikayin","year":"2022","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.jad.2024.04.039_bb0225","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.102127","article-title":"Ketamine for the treatment of major depression: a systematic review and meta-analysis","volume":"62","author":"Nikolin","year":"2023","journal-title":"eClinicalMedicine"},{"key":"10.1016\/j.jad.2024.04.039_bb0230","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.jagp.2019.10.008","article-title":"Efficacy and safety of esketamine nasal spray plus an oral antidepressant in elderly patients with treatment-resistant depression\u2014TRANSFORM-3","volume":"28","author":"Ochs-Ross","year":"2020","journal-title":"Am. J. Geriatr. Psychiatry"},{"key":"10.1016\/j.jad.2024.04.039_bb0235","series-title":"Principles of Biostatistics","author":"Pagano","year":"2018"},{"key":"10.1016\/j.jad.2024.04.039_bb0240","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.jad.2024.04.039_bb0245","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1176\/appi.ajp.2018.18070834","article-title":"Single, repeated, and maintenance ketamine infusions for treatment-resistant depression: a randomized controlled trial","volume":"176","author":"Phillips","year":"2019","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jad.2024.04.039_bb0250","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1176\/appi.ajp.2019.19020172","article-title":"Efficacy and safety of flexibly dosed esketamine nasal spray combined with a newly initiated oral antidepressant in treatment-resistant depression: a randomized double-blind active-controlled study","volume":"176","author":"Popova","year":"2019","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jad.2024.04.039_bb0255","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1002\/da.22253","article-title":"Effects of ketamine on explicit and implicit suicidal cognition: a randomized controlled trial in the treatment-resistant depression","volume":"31","author":"Price","year":"2014","journal-title":"Depress. Anxiety"},{"key":"10.1016\/j.jad.2024.04.039_bb0260","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1056\/NEJMoa2304145","article-title":"Esketamine nasal spray versus quetiapine for treatment-resistant depression","volume":"389","author":"Reif","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jad.2024.04.039_bb0265","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1046\/J.1524-4733.2002.55150.x","article-title":"Odds ratio, relative risk, absolute risk reduction, and the number needed to treat\u2014which of these should we use?","volume":"5","author":"Schechtman","year":"2002","journal-title":"Value Health"},{"key":"10.1016\/j.jad.2024.04.039_bb0270","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1038\/s41398-020-00897-0","article-title":"A randomized, double-blind, active placebo-controlled study of efficacy, safety, and durability of repeated vs single subanesthetic ketamine for treatment-resistant depression","volume":"10","author":"Shiroma","year":"2020","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.jad.2024.04.039_bb0275","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.biopsych.2015.10.018","article-title":"Intravenous esketamine in adult treatment-resistant depression: a double-blind, double-randomization, placebo-controlled study","volume":"80","author":"Singh","year":"2016","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.jad.2024.04.039_bb0280","first-page":"816","article-title":"A double-blind, randomized, placebo-controlled, dose-frequency study of intravenous ketamine in patients with treatment-resistant depression","volume":"173","author":"Singh","year":"2016","journal-title":"Biol. Psychiatry"},{"issue":"2","key":"10.1016\/j.jad.2024.04.039_bb0285","doi-asserted-by":"crossref","first-page":"45331","DOI":"10.4088\/JCP.22m14548","article-title":"Comparative effectiveness of intravenous ketamine and intranasal esketamine in clinical practice among patients with treatment-refractory depression: an observational study","volume":"84","author":"Singh","year":"2023","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2024.04.039_bb0290","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1136\/bmj.318.7197.1548","article-title":"Numbers needed to treat derived from meta-analyses---sometimes informative, usually misleading","volume":"318","author":"Smeeth","year":"1999","journal-title":"BMJ"},{"key":"10.1016\/j.jad.2024.04.039_bb0295","first-page":"907","article-title":"Maintenance ketamine treatment for depression: a systematic review of efficacy, safety, and tolerability","volume":"9","author":"Smith-Apeldoorn","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.jad.2024.04.039_bb0300","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1038\/npp.2017.94","article-title":"Dose-related effects of adjunctive ketamine in Taiwanese patients with treatment-resistant depression","volume":"42","author":"Su","year":"2017","journal-title":"Neuropsychopharmacol"},{"key":"10.1016\/j.jad.2024.04.039_bb0305","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1093\/ijnp\/pyad014","article-title":"A randomized, double-blind, midazolam-controlled trial of low-dose ketamine infusion in patients with treatment-resistant depression and prominent suicidal ideation","volume":"26","author":"Su","year":"2023","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.jad.2024.04.039_bb0310","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1186\/s12888-021-03538-y","article-title":"Efficacy and safety of fixed doses of intranasal Esketamine as an add-on therapy to Oral antidepressants in Japanese patients with treatment-resistant depression: a phase 2b randomized clinical study","volume":"21","author":"Takahashi","year":"2021","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.jad.2024.04.039_bb0315","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/s41398-020-0844-4","article-title":"A randomized placebo-controlled PET study of ketamine\u2019s effect on serotonin1B receptor binding in patients with SSRI-resistant depression","volume":"10","author":"Tiger","year":"2020","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.jad.2024.04.039_bb0320","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1038\/npp.2011.306","article-title":"Randomized, placebo-controlled trials of antidepressants for acute major depression: thirty-year meta-analytic review","volume":"37","author":"Undurraga","year":"2012","journal-title":"Neuropsychopharmacol"},{"key":"10.1016\/j.jad.2024.04.039_bb0325","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1177\/02698811211013579","article-title":"Efficacy and tolerability of combination treatments for major depression: antidepressants plus second-generation antipsychotics vs. esketamine vs. lithium","volume":"35","author":"V\u00e1zquez","year":"2021","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.jad.2024.04.039_bb0055","unstructured":"Wilkinson, S., Sanacora, G., 2023. Comparative Effectiveness of Racemic Ketamine versus S-Ketamine for Depression | PCORI [Internet]. URL https:\/\/www.pcori.org\/research-results\/2023\/comparative-effectiveness-racemic-ketamine-versus-s-ketamine-depression (accessed 3.15.24)."},{"key":"10.1016\/j.jad.2024.04.039_bb0330","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1001\/archpsyc.63.8.856","article-title":"A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression","volume":"63","author":"Zarate","year":"2006","journal-title":"Arch. Gen. Psychiatry"}],"container-title":["Journal of Affective Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165032724006402?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165032724006402?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,16]],"date-time":"2025-03-16T22:13:26Z","timestamp":1742163206000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165032724006402"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":67,"alternative-id":["S0165032724006402"],"URL":"https:\/\/doi.org\/10.1016\/j.jad.2024.04.039","relation":{},"ISSN":["0165-0327"],"issn-type":[{"value":"0165-0327","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Number needed to treat (NNT) for ketamine and esketamine in adults with treatment-resistant depression: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Journal of Affective Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jad.2024.04.039","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}